Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Ling

Showing results (51-60 of 55) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 55 results.
Journal for Immunotherapy of Cancer|April 11, 2024
Oral PD-L1 inhibitor GS-4224 selectively engages PD-L1 high cells and elicits pharmacodynamic responses in patients with advanced solid tumorsJared M Odegard, Ahmed A Othman, Kai-Wen Lin, et al.
BMC Plant Biology|January 17, 2012
A genomics approach to understanding the role of auxin in apple (Malus x domestica) fruit size controlFanny Devoghalaere, Thomas Doucen, Baptiste Guitton, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 11, 2009
The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of AmericaScott W Grimm, Heidi J Einolf, Steven D Hall, et al.
Antiviral Therapy|July 16, 2020
Safety, pharmacokinetics and pharmacodynamics of selgantolimod, an oral Toll-like receptor 8 agonist: a Phase Ia study in healthy subjectsMaribel Reyes, Justin D Lutz, Audrey H Lau, et al.
Nature|July 3, 2020
Clinical targeting of HIV capsid protein with a long-acting small moleculeJohn O Link, Martin S Rhee, Winston C Tse, et al.
Pageof 6

Showing results (51-60 of 55) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 55 results.
Journal for Immunotherapy of Cancer|April 11, 2024
Oral PD-L1 inhibitor GS-4224 selectively engages PD-L1 high cells and elicits pharmacodynamic responses in patients with advanced solid tumorsJared M Odegard, Ahmed A Othman, Kai-Wen Lin, et al.
BMC Plant Biology|January 17, 2012
A genomics approach to understanding the role of auxin in apple (Malus x domestica) fruit size controlFanny Devoghalaere, Thomas Doucen, Baptiste Guitton, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 11, 2009
The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of AmericaScott W Grimm, Heidi J Einolf, Steven D Hall, et al.
Antiviral Therapy|July 16, 2020
Safety, pharmacokinetics and pharmacodynamics of selgantolimod, an oral Toll-like receptor 8 agonist: a Phase Ia study in healthy subjectsMaribel Reyes, Justin D Lutz, Audrey H Lau, et al.
Nature|July 3, 2020
Clinical targeting of HIV capsid protein with a long-acting small moleculeJohn O Link, Martin S Rhee, Winston C Tse, et al.
Pageof 6